{
  "id": "mild-cognitive-impairment",
  "title": "Mild Cognitive Impairment (MCI)",
  "version": "1.1",
  "icd10": [
    "** G31.84 (Mild cognitive impairment)",
    "F06.7 (Mild neurocognitive disorder)",
    "R41.81 (Age-related cognitive decline)"
  ],
  "scope": "** Outpatient-focused evaluation for MCI, identification of reversible causes, subtype classification (amnestic vs non-amnestic), risk factor modification, monitoring for progression, and symptomatic treatment. Includes guidance on disease-modifying therapy eligibility (anti-amyloid agents) and advance care planning.",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "Essential/Core Labs (Reversible Causes Screen)": [
        {
          "item": "CBC with differential (CPT 85025)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Anemia, infection, or malignancy contributing to cognitive changes",
          "target": "Normal"
        },
        {
          "item": "CMP (CPT 80053)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Hyponatremia, uremia, hypercalcemia, hepatic encephalopathy as reversible causes",
          "target": "Normal electrolytes, renal, hepatic function"
        },
        {
          "item": "TSH (CPT 84443)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Hypothyroidism is reversible cause of cognitive impairment",
          "target": "0.4-4.0 mIU/L"
        },
        {
          "item": "Vitamin B12 (CPT 82607)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Deficiency causes reversible cognitive impairment; common in elderly",
          "target": ">300 pg/mL (>400 pg/mL optimal for neurological function)"
        },
        {
          "item": "Folate (CPT 82746)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Deficiency contributes to cognitive impairment; check with B12",
          "target": ">3 ng/mL"
        },
        {
          "item": "HbA1c (CPT 83036)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Diabetes management affects cognition; vascular risk factor",
          "target": "<7% (individualize in elderly)"
        },
        {
          "item": "Fasting lipid panel (CPT 80061)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Vascular risk factor assessment; hyperlipidemia accelerates cognitive decline",
          "target": "LDL <100 mg/dL; <70 if established CVD"
        },
        {
          "item": "Glucose, fasting (CPT 82947)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Diabetes screening; glycemic control affects cognition",
          "target": "70-100 mg/dL"
        }
      ],
      "Extended Workup (Second-line)": [
        {
          "item": "RPR (CPT 86592)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Neurosyphilis is rare but treatable cause of cognitive impairment",
          "target": "Nonreactive"
        },
        {
          "item": "HIV-1/2 antigen/antibody (CPT 87389)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "HIV-associated neurocognitive disorder; if risk factors present",
          "target": "Negative"
        },
        {
          "item": "Vitamin D, 25-OH (CPT 82306)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Deficiency associated with cognitive decline and dementia risk",
          "target": ">30 ng/mL"
        },
        {
          "item": "Homocysteine (CPT 83090)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Elevated levels associated with Alzheimer's disease and vascular cognitive impairment",
          "target": "<15 μmol/L"
        },
        {
          "item": "ESR (CPT 85652), CRP (CPT 86140)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Inflammatory or autoimmune causes; vasculitis screen",
          "target": "Normal"
        },
        {
          "item": "Urinalysis (CPT 81003)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "UTI in elderly can present as cognitive changes; rule out reversible cause",
          "target": "Negative for infection"
        },
        {
          "item": "Methylmalonic acid (CPT 83921)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "More sensitive than B12 level for functional B12 deficiency",
          "target": "<0.4 μmol/L"
        }
      ],
      "Rare/Specialized (Refractory or Atypical)": [
        {
          "item": "Heavy metal panel: lead (CPT 83655), mercury (CPT 83825), arsenic (CPT 82175)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Toxic exposure history; occupational risk",
          "target": "Normal"
        },
        {
          "item": "Copper (CPT 82525), Ceruloplasmin (CPT 82390)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Wilson's disease if age <50; hepatic symptoms",
          "target": "Normal"
        },
        {
          "item": "Paraneoplastic antibody panel (CPT 86255)",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Autoimmune cognitive impairment; unexplained rapid progression",
          "target": "Negative"
        },
        {
          "item": "Anti-neuronal antibodies: NMDA-R, LGI1, CASPR2, GABA-B (CPT 86235)",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Autoimmune encephalitis presenting as MCI",
          "target": "Negative"
        },
        {
          "item": "APOE genotyping (CPT 81401)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Risk stratification for AD progression; anti-amyloid therapy planning",
          "target": "Informational (APOE4 increases risk)"
        },
        {
          "item": "Genetic testing: PSEN1, PSEN2, APP (CPT 81406)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Familial early-onset AD (<65); family history of early-onset dementia",
          "target": "No pathogenic variants"
        },
        {
          "item": "Lyme serology (CPT 86618)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Endemic area; outdoor exposure; systemic symptoms",
          "target": "Negative"
        }
      ],
      "Lumbar Puncture": [
        {
          "item": "Cell count, protein, glucose (CPT 89050, 89051)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Rule out infection, inflammation",
          "target": "WBC <5, protein <45 mg/dL, glucose >60% serum"
        },
        {
          "item": "CSF Amyloid-beta 1-42 (CPT 83519)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Low in Alzheimer's pathology; biomarker confirmation",
          "target": "Low Aβ42 (<600 pg/mL) suggests AD pathology"
        },
        {
          "item": "CSF total tau (CPT 83519)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Elevated in neurodegeneration; nonspecific",
          "target": "Mildly elevated in MCI due to AD; marked elevation suggests rapid progression"
        },
        {
          "item": "CSF phosphorylated tau 181 (CPT 83519)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Specific for AD pathology; predictor of progression",
          "target": "Elevated p-tau with low Aβ42 = high risk of AD progression"
        },
        {
          "item": "CSF Aβ42/Aβ40 ratio (CPT 83519)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "More accurate than Aβ42 alone for amyloid status",
          "target": "<0.05-0.08 suggests amyloid positivity (assay-dependent)"
        },
        {
          "item": "CSF neurofilament light chain (CPT 83519)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Nonspecific neurodegeneration marker; prognostic",
          "target": "Elevated suggests active neurodegeneration"
        },
        {
          "item": "VDRL (CPT 86592)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Neurosyphilis if RPR positive or high suspicion",
          "target": "Nonreactive"
        }
      ]
    },
    "Imaging & Studies": {
      "Essential/First-line": [
        {
          "item": "MRI Brain without contrast (CPT 70551)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "At initial evaluation",
          "target": "Hippocampal volume, medial temporal atrophy (Scheltens scale), white matter disease burden, rule out structural causes (tumor, SDH, NPH)",
          "contraindications": "MRI-incompatible devices"
        },
        {
          "item": "Neuropsychological testing, formal (CPT 96132, 96133)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "At diagnosis; gold standard for MCI characterization",
          "target": "Objective impairment 1-1.5 SD below age/education norms; preserved ADLs; characterize domain(s) affected",
          "contraindications": "None"
        },
        {
          "item": "Mini-Mental State Examination (CPT 96116)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Screening; serial monitoring",
          "target": "24-30 (MCI often 24-27); <24 suggests dementia",
          "contraindications": "None"
        },
        {
          "item": "Montreal Cognitive Assessment (CPT 96116)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "More sensitive than MMSE for MCI",
          "target": "<26 abnormal; typically 18-25 in MCI",
          "contraindications": "None"
        }
      ],
      "Extended": [
        {
          "item": "CT Head non-contrast (CPT 70450)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "If MRI contraindicated or unavailable",
          "target": "Rule out mass, hemorrhage, hydrocephalus",
          "contraindications": "None"
        },
        {
          "item": "MRI Brain volumetrics (CPT 70551)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Quantitative assessment; research/clinical trials",
          "target": "Hippocampal volume percentile for age; whole brain atrophy rate",
          "contraindications": "MRI contraindications"
        },
        {
          "item": "FDG-PET Brain (CPT 78816)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Differentiate underlying pathology when diagnosis uncertain",
          "target": "AD pattern: temporoparietal hypometabolism; FTD: frontal/temporal hypometabolism",
          "contraindications": "None"
        },
        {
          "item": "Amyloid PET (CPT 78811)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Diagnostic uncertainty; early-onset; anti-amyloid therapy eligibility",
          "target": "Positive confirms amyloid pathology (at risk for AD); negative makes AD unlikely",
          "contraindications": "None"
        },
        {
          "item": "Sleep study, polysomnography (CPT 95810)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Sleep apnea screening; sleep disturbance affecting cognition",
          "target": "AHI <5 normal; treat if elevated",
          "contraindications": "None"
        },
        {
          "item": "EEG (CPT 95816)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Atypical features; concern for seizures or encephalopathy",
          "target": "Normal or mild nonspecific slowing in MCI",
          "contraindications": "None"
        }
      ],
      "Rare/Specialized": [
        {
          "item": "Tau PET (CPT 78811)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "Research; disease staging; clinical trial eligibility",
          "target": "Pattern correlates with clinical syndrome; elevated tau predicts faster progression",
          "contraindications": "None"
        },
        {
          "item": "DaTscan (CPT 78607)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "MCI with parkinsonism; differentiate DLB prodrome",
          "target": "Reduced uptake suggests Lewy body pathology",
          "contraindications": "Iodine hypersensitivity"
        },
        {
          "item": "SPECT perfusion (CPT 78607)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "Alternative to PET if unavailable",
          "target": "Regional hypoperfusion patterns",
          "contraindications": "None"
        },
        {
          "item": "MRI with SWI/GRE sequences (CPT 70551)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Cerebral amyloid angiopathy; microbleed assessment",
          "target": "Lobar microbleeds suggest CAA; affects anti-amyloid eligibility",
          "contraindications": "MRI contraindications"
        }
      ]
    },
    "Treatment": {
      "Acute/Emergent": [
        {
          "item": "Treat reversible causes",
          "route": "Various",
          "indication": "Identified metabolic, nutritional, or infectious etiology",
          "dosing": {
            "doseOptions": [
              {
                "text": "Per cause",
                "orderSentence": "Treat reversible causes Per cause Various"
              }
            ],
            "route": "Various",
            "instructions": "Correct hypothyroidism, replace B12/folate, treat infections, adjust medications",
            "orderSentence": "Treat reversible causes Per cause Various"
          },
          "contraindications": "Depends on intervention",
          "monitoring": "Cognitive reassessment 3-6 months after treatment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Thiamine",
          "route": "IV/PO",
          "indication": "Suspected Wernicke's; alcoholism; malnutrition",
          "dosing": {
            "doseOptions": [
              {
                "text": "500 mg",
                "orderSentence": "Thiamine 500 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "500 mg IV TID x 3 days if Wernicke suspected; then 100 mg PO daily maintenance",
            "orderSentence": "Thiamine 500 mg IV"
          },
          "contraindications": "None",
          "monitoring": "Clinical improvement",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Vitamin B12",
          "route": "IM/PO",
          "indication": "B12 deficiency (<300 pg/mL or elevated MMA)",
          "dosing": {
            "doseOptions": [
              {
                "text": "1000 mcg",
                "orderSentence": "Vitamin B12 1000 mcg IM"
              }
            ],
            "route": "IM",
            "instructions": "1000 mcg IM daily x 7d, then weekly x 4wk, then monthly; or high-dose oral 1000-2000 mcg daily",
            "orderSentence": "Vitamin B12 1000 mcg IM"
          },
          "contraindications": "None",
          "monitoring": "B12 level, MMA at 3 months; neurological improvement over months",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Folate",
          "route": "PO",
          "indication": "Folate deficiency",
          "dosing": {
            "doseOptions": [
              {
                "text": "1 mg",
                "orderSentence": "Folate 1 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "1 mg PO daily; ensure B12 adequate before treating to avoid masking deficiency",
            "orderSentence": "Folate 1 mg PO"
          },
          "contraindications": "None",
          "monitoring": "Folate level at 3 months",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Symptomatic Treatments": [
        {
          "item": "Donepezil",
          "route": "PO",
          "indication": "MCI with high likelihood of AD pathology (amnestic MCI, positive biomarkers); modest symptomatic benefit",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg",
                "orderSentence": "Donepezil 5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 5 mg qHS x 4-6 weeks; may increase to 10 mg qHS; limited evidence in MCI but may offer modest benefit",
            "orderSentence": "Donepezil 5 mg PO"
          },
          "contraindications": "Sick sinus syndrome; GI bleeding; severe COPD",
          "monitoring": "Bradycardia, GI symptoms, vivid dreams; limited efficacy data in MCI",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Rivastigmine patch",
          "route": "TD",
          "indication": "Alternative to donepezil; better GI tolerability; MCI with positive AD biomarkers",
          "dosing": {
            "doseOptions": [
              {
                "text": "4.6 mg/24hr",
                "orderSentence": "Rivastigmine patch 4.6 mg/24hr TD"
              }
            ],
            "route": "TD",
            "instructions": "Start 4.6 mg/24hr; increase q4wk to 9.5 mg/24hr; limited evidence in MCI",
            "orderSentence": "Rivastigmine patch 4.6 mg/24hr TD"
          },
          "contraindications": "Sick sinus syndrome; GI bleeding; severe COPD; severe hepatic impairment",
          "monitoring": "Skin irritation, GI symptoms",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Citalopram",
          "route": "PO",
          "indication": "Depression contributing to cognitive symptoms (pseudodementia component)",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg",
                "orderSentence": "Citalopram 10 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 10 mg daily; max 20 mg in elderly due to QT risk",
            "orderSentence": "Citalopram 10 mg PO"
          },
          "contraindications": "QT prolongation; concurrent QT-prolonging drugs",
          "monitoring": "QTc at baseline and if dose >20 mg",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Sertraline",
          "route": "PO",
          "indication": "Depression; anxiety contributing to cognitive complaints",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg",
                "orderSentence": "Sertraline 25 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25 mg daily; titrate by 25 mg q1-2wk; typical 50-100 mg",
            "orderSentence": "Sertraline 25 mg PO"
          },
          "contraindications": "MAOIs; caution with bleeding risk",
          "monitoring": "GI upset initially; reassess cognition after mood improves",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Escitalopram",
          "route": "PO",
          "indication": "Depression; anxiety with cognitive symptoms",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg",
                "orderSentence": "Escitalopram 5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 5 mg daily; increase to 10 mg after 1 week; max 10 mg in elderly",
            "orderSentence": "Escitalopram 5 mg PO"
          },
          "contraindications": "QT prolongation; MAOIs",
          "monitoring": "QTc monitoring",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Mirtazapine",
          "route": "PO",
          "indication": "Depression with poor appetite, insomnia, and weight loss",
          "dosing": {
            "doseOptions": [
              {
                "text": "7.5 mg",
                "orderSentence": "Mirtazapine 7.5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 7.5-15 mg qHS; may increase to 30 mg qHS",
            "orderSentence": "Mirtazapine 7.5 mg PO"
          },
          "contraindications": "MAOIs",
          "monitoring": "Weight gain (may be beneficial), sedation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Bupropion",
          "route": "PO",
          "indication": "Depression with fatigue; avoid if seizure risk",
          "dosing": {
            "doseOptions": [
              {
                "text": "150 mg",
                "orderSentence": "Bupropion 150 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 100 mg BID or 150 mg SR daily; increase after 1 week; max 300 mg/day",
            "orderSentence": "Bupropion 150 mg PO"
          },
          "contraindications": "Seizure disorder; eating disorder; abrupt alcohol/benzo withdrawal",
          "monitoring": "Seizure risk; may improve alertness",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Trazodone",
          "route": "PO",
          "indication": "Insomnia in MCI patients",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg",
                "orderSentence": "Trazodone 25 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25-50 mg qHS; titrate to effect; typical 50-100 mg qHS",
            "orderSentence": "Trazodone 25 mg PO"
          },
          "contraindications": "Concurrent MAOIs; QT prolongation",
          "monitoring": "Orthostatic hypotension, morning sedation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Melatonin",
          "route": "PO",
          "indication": "Sleep disturbance; circadian rhythm support",
          "dosing": {
            "doseOptions": [
              {
                "text": "1 mg",
                "orderSentence": "Melatonin 1 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 1-3 mg qHS; may increase to 5 mg; take 30 min before bed",
            "orderSentence": "Melatonin 1 mg PO"
          },
          "contraindications": "None",
          "monitoring": "Daytime sedation; limited long-term data",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Cardiovascular Risk Factor Management": [
        {
          "item": "Atorvastatin",
          "route": "PO",
          "indication": "Hyperlipidemia; vascular risk reduction; may slow cognitive decline",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg",
                "orderSentence": "Atorvastatin 10 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 10-20 mg daily; titrate to LDL goal; target LDL <100 (or <70 if established CVD)",
            "orderSentence": "Atorvastatin 10 mg PO"
          },
          "contraindications": "Active liver disease; pregnancy",
          "monitoring": "LFTs at baseline; lipid panel q3-6mo initially",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Rosuvastatin",
          "route": "PO",
          "indication": "Hyperlipidemia; alternative statin",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg",
                "orderSentence": "Rosuvastatin 5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 5-10 mg daily; adjust to LDL goal",
            "orderSentence": "Rosuvastatin 5 mg PO"
          },
          "contraindications": "Active liver disease; severe renal impairment (dose adjust)",
          "monitoring": "LFTs, lipid panel",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Lisinopril",
          "route": "PO",
          "indication": "Hypertension; target BP <130/80 for vascular protection",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg",
                "orderSentence": "Lisinopril 5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 5-10 mg daily; titrate q2wk to BP goal",
            "orderSentence": "Lisinopril 5 mg PO"
          },
          "contraindications": "Angioedema history; pregnancy; bilateral renal artery stenosis",
          "monitoring": "K+, Cr, BP; cough",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Amlodipine",
          "route": "PO",
          "indication": "Hypertension; especially if ACE-I intolerant",
          "dosing": {
            "doseOptions": [
              {
                "text": "2.5 mg",
                "orderSentence": "Amlodipine 2.5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 2.5-5 mg daily; increase q2wk; max 10 mg",
            "orderSentence": "Amlodipine 2.5 mg PO"
          },
          "contraindications": "Severe aortic stenosis",
          "monitoring": "Peripheral edema, BP",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Losartan",
          "route": "PO",
          "indication": "Hypertension; alternative if ACE-I intolerant",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg",
                "orderSentence": "Losartan 25 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25-50 mg daily; titrate to BP goal; max 100 mg",
            "orderSentence": "Losartan 25 mg PO"
          },
          "contraindications": "Angioedema history; pregnancy; bilateral renal artery stenosis",
          "monitoring": "K+, Cr, BP",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Metformin",
          "route": "PO",
          "indication": "Type 2 diabetes; potential neuroprotective effects",
          "dosing": {
            "doseOptions": [
              {
                "text": "500 mg",
                "orderSentence": "Metformin 500 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 500 mg daily with meal; increase by 500 mg weekly; max 2000 mg/day",
            "orderSentence": "Metformin 500 mg PO"
          },
          "contraindications": "eGFR <30; risk of lactic acidosis",
          "monitoring": "HbA1c q3mo; B12 annually (metformin reduces absorption)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Aspirin (low-dose)",
          "route": "PO",
          "indication": "Secondary prevention if established CVD; not for primary prevention in MCI",
          "dosing": {
            "doseOptions": [
              {
                "text": "81 mg",
                "orderSentence": "Aspirin (low-dose) 81 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "81 mg daily; only if established CVD or high vascular risk",
            "orderSentence": "Aspirin (low-dose) 81 mg PO"
          },
          "contraindications": "Active bleeding; aspirin allergy; high bleeding risk",
          "monitoring": "GI symptoms; bleeding",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Disease-Modifying Therapies (Anti-Amyloid)": [
        {
          "item": "Lecanemab (Leqembi)",
          "route": "IV",
          "indication": "MCI due to AD with confirmed amyloid pathology (positive amyloid PET or CSF biomarkers)",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg/kg",
                "orderSentence": "Lecanemab (Leqembi) 10 mg/kg IV"
              }
            ],
            "route": "IV",
            "instructions": "10 mg/kg IV every 2 weeks; infuse over 1 hour; continue as long as benefit maintained",
            "orderSentence": "Lecanemab (Leqembi) 10 mg/kg IV"
          },
          "pretreatment": "Amyloid PET or CSF confirming amyloid positivity; MRI baseline (within 1 year); APOE genotyping recommended; informed consent for ARIA risk",
          "contraindications": ">4 microbleeds on MRI; superficial siderosis; anticoagulation (increased ARIA risk); recent stroke/TIA",
          "monitoring": "MRI at baseline, weeks 14, 52, 78; monitor for ARIA-E/H symptoms (headache, confusion, vision changes)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Donanemab (Kisunla)",
          "route": "IV",
          "indication": "MCI due to AD with confirmed amyloid and intermediate/high tau pathology",
          "dosing": {
            "doseOptions": [
              {
                "text": "700 mg",
                "orderSentence": "Donanemab (Kisunla) 700 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "700 mg q4wk x 3 doses, then 1400 mg q4wk until amyloid cleared (PET-guided discontinuation)",
            "orderSentence": "Donanemab (Kisunla) 700 mg IV"
          },
          "pretreatment": "Amyloid PET positive; tau PET intermediate/high; MRI baseline; APOE genotyping",
          "contraindications": "APOE4 homozygotes have higher ARIA risk; >4 microbleeds; anticoagulation",
          "monitoring": "MRI at baseline, weeks 16, 24, 52, 76; amyloid PET to guide discontinuation",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        }
      ]
    },
    "Other Recommendations": {
      "Referrals & Consults": [
        {
          "item": "Neurology/Cognitive neurology for MCI subtype characterization, biomarker interpretation, and treatment planning",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Neuropsychology for comprehensive cognitive testing to establish baseline, characterize affected domains, and distinguish MCI subtypes",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Geriatrics for comprehensive geriatric assessment, polypharmacy review, and functional optimization",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Occupational therapy for cognitive strategies, compensatory techniques, and home safety evaluation",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Occupational therapy driving evaluation to assess fitness to drive given cognitive impairment",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Social work for community resources, support services, and early care planning guidance",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Speech therapy for communication strategies if language domain affected (non-amnestic MCI)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Sleep medicine for sleep apnea evaluation if symptoms present (snoring, daytime sleepiness, witnessed apneas)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Psychiatry for depression evaluation if significant mood symptoms confounding cognitive assessment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Genetics counseling if early-onset (<65), family history of early-onset dementia, or considering genetic testing",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Clinical trial referral for eligible patients interested in research studies targeting MCI and early AD",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Elder law attorney for advance directives, healthcare proxy, and financial planning while patient has full capacity",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "PCP follow-up for cardiovascular risk factor management and coordination of vascular prevention",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Patient Instructions": [
        {
          "item": "Return if sudden confusion worsens or new neurological symptoms develop which may indicate stroke or other acute process",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Complete advance directives and establish healthcare proxy NOW while you have full capacity to make decisions",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Consider long-term care preferences, financial planning, and legal arrangements with family while fully competent",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Discuss driving safety with physician; formal driving evaluation recommended as MCI may affect reaction time and judgment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Use memory aids (calendars, smartphone reminders, pill organizers, written lists) to compensate for memory difficulties",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Keep a consistent daily routine which helps with memory and reduces confusion",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Take all medications as prescribed; bring medication list to all appointments",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Return for follow-up cognitive testing every 6-12 months to monitor for progression",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Report new memory concerns, personality changes, or functional difficulties to physician promptly",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Avoid anticholinergic medications (diphenhydramine, PM sleep aids) as they can worsen cognition",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        }
      ],
      "Lifestyle & Prevention": [
        {
          "item": "Engage in regular aerobic exercise (150 minutes/week moderate intensity) which may slow cognitive decline and improve brain health",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Follow Mediterranean or MIND diet emphasizing vegetables, berries, fish, nuts, whole grains, and olive oil to reduce dementia risk",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Participate in cognitively stimulating activities (reading, puzzles, learning new skills, social engagement) to build cognitive reserve",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Maintain active social connections and relationships as social isolation is a modifiable dementia risk factor",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Achieve adequate sleep (7-8 hours nightly) and treat sleep disorders (CPAP for sleep apnea) as poor sleep accelerates cognitive decline",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Cardiovascular risk factor control with target BP <130/80, HbA1c <7%, LDL <100 to reduce vascular contribution to cognitive decline",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Address hearing loss with hearing aids as untreated hearing loss is a modifiable risk factor for cognitive decline",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Limit alcohol to maximum 1 drink daily as excess alcohol accelerates brain atrophy and cognitive decline",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Smoking cessation to reduce vascular risk and improve overall brain health",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Manage stress through relaxation techniques, mindfulness, or counseling as chronic stress impairs cognition",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Review all medications with physician to identify and discontinue drugs that impair cognition (anticholinergics, benzodiazepines, opioids)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        }
      ]
    }
  },
  "differential": [
    {
      "diagnosis": "Normal aging",
      "features": "Subjective memory concerns without objective impairment; no functional decline; normal neuropsych testing",
      "tests": "Neuropsychological testing within 1 SD of norms"
    },
    {
      "diagnosis": "Subjective cognitive decline",
      "features": "Memory complaints but normal objective testing; may be earliest preclinical stage",
      "tests": "Neuropsychological testing normal; monitor annually"
    },
    {
      "diagnosis": "Depression (pseudodementia)",
      "features": "Prominent mood symptoms; often aware of and distressed by deficits; improves with antidepressants",
      "tests": "GDS, PHQ-9; trial of antidepressant; reassess cognition"
    },
    {
      "diagnosis": "Medication-induced cognitive impairment",
      "features": "Temporal relationship to medication initiation; improvement with discontinuation",
      "tests": "Medication review; trial discontinuation of suspect agents"
    },
    {
      "diagnosis": "Sleep apnea-related cognitive impairment",
      "features": "Excessive daytime sleepiness; snoring; morning headaches; reversible with CPAP",
      "tests": "Polysomnography; cognitive reassessment after CPAP"
    },
    {
      "diagnosis": "Alzheimer's disease (dementia stage)",
      "features": "Functional impairment in ADLs (not just IADLs); more severe cognitive deficits",
      "tests": "Functional assessment; neuropsychological testing"
    },
    {
      "diagnosis": "Vascular cognitive impairment",
      "features": "Stepwise decline; focal findings; executive dysfunction prominent; significant white matter disease",
      "tests": "MRI with confluent white matter disease; vascular risk factors"
    },
    {
      "diagnosis": "Dementia with Lewy bodies (prodromal)",
      "features": "Visual hallucinations; REM sleep behavior disorder; parkinsonism; fluctuating cognition",
      "tests": "DaTscan; clinical features; sleep study for RBD"
    },
    {
      "diagnosis": "Frontotemporal dementia (prodromal)",
      "features": "Behavioral/personality changes; disinhibition; apathy; language variants; typically <65",
      "tests": "FDG-PET frontal/temporal hypometabolism; neuropsychological profile"
    },
    {
      "diagnosis": "Thyroid dysfunction",
      "features": "Fatigue, weight changes, cold/heat intolerance; reversible with treatment",
      "tests": "TSH, free T4; reassess after treatment"
    },
    {
      "diagnosis": "Vitamin B12 deficiency",
      "features": "Peripheral neuropathy; macrocytic anemia; reversible with replacement",
      "tests": "B12, MMA; improvement with supplementation"
    }
  ],
  "evidence": [
    {
      "recommendation": "MCI diagnostic criteria and subtypes",
      "evidenceLevel": "Class I, Level A",
      "source": "[Petersen et al. Arch Neurol 2004](https://pubmed.ncbi.nlm.nih.gov/15477521/); [Albert et al. Alzheimers Dement 2011](https://pubmed.ncbi.nlm.nih.gov/21514249/)"
    },
    {
      "recommendation": "Neuropsychological testing for MCI diagnosis",
      "evidenceLevel": "Class I, Level A",
      "source": "[AAN Practice Parameter 2018](https://pubmed.ncbi.nlm.nih.gov/29282327/)"
    },
    {
      "recommendation": "CSF biomarkers for AD pathology",
      "evidenceLevel": "Class I, Level A",
      "source": "[Hansson et al. Lancet Neurol 2018](https://pubmed.ncbi.nlm.nih.gov/30244989/)"
    },
    {
      "recommendation": "Amyloid PET for AD diagnosis in MCI",
      "evidenceLevel": "Class I, Level A",
      "source": "[Johnson et al. Alzheimers Dement 2013](https://pubmed.ncbi.nlm.nih.gov/23360977/)"
    },
    {
      "recommendation": "Cholinesterase inhibitors limited benefit in MCI",
      "evidenceLevel": "Class I, Level B",
      "source": "[Petersen et al. NEJM 2005](https://pubmed.ncbi.nlm.nih.gov/15800226/); [Russ & Morling, Cochrane 2012](https://pubmed.ncbi.nlm.nih.gov/22972104/)"
    },
    {
      "recommendation": "Lecanemab slows decline in MCI due to AD",
      "evidenceLevel": "Class I, Level A",
      "source": "[van Dyck et al. NEJM 2023 (Clarity AD)](https://pubmed.ncbi.nlm.nih.gov/36449413/)"
    },
    {
      "recommendation": "Donanemab slows decline in early AD",
      "evidenceLevel": "Class I, Level A",
      "source": "[Sims et al. JAMA 2023 (TRAILBLAZER-ALZ 2)](https://pubmed.ncbi.nlm.nih.gov/37459141/)"
    },
    {
      "recommendation": "Physical exercise may slow cognitive decline",
      "evidenceLevel": "Class II, Level B",
      "source": "[Livingston et al. Lancet 2020 (Lancet Commission on Dementia)](https://pubmed.ncbi.nlm.nih.gov/32738937/)"
    },
    {
      "recommendation": "Mediterranean/MIND diet reduces dementia risk",
      "evidenceLevel": "Class II, Level B",
      "source": "[Morris et al. Alzheimers Dement 2015](https://pubmed.ncbi.nlm.nih.gov/25681666/)"
    },
    {
      "recommendation": "Cardiovascular risk factor control protects cognition",
      "evidenceLevel": "Class I, Level A",
      "source": "[Ngandu et al. Lancet 2015 (FINGER trial)](https://pubmed.ncbi.nlm.nih.gov/25771249/)"
    },
    {
      "recommendation": "Sleep apnea treatment improves cognition",
      "evidenceLevel": "Class II, Level B",
      "source": "[Osorio et al. Neurology 2015](https://pubmed.ncbi.nlm.nih.gov/25878179/)"
    },
    {
      "recommendation": "MCI progression rate to dementia (~10-15%/year)",
      "evidenceLevel": "Epidemiological",
      "source": "[Mitchell & Shiri-Feshki, Acta Psychiatr Scand 2009](https://pubmed.ncbi.nlm.nih.gov/19327298/)"
    },
    {
      "recommendation": "Hearing loss as modifiable dementia risk factor",
      "evidenceLevel": "Class II, Level B",
      "source": "[Lin et al. Arch Neurol 2011](https://pubmed.ncbi.nlm.nih.gov/21320988/)"
    },
    {
      "recommendation": "Modifiable risk factors for dementia prevention",
      "evidenceLevel": "Class II, Level A",
      "source": "[Livingston et al. Lancet 2024 (Lancet Commission Update)](https://pubmed.ncbi.nlm.nih.gov/39096926/)"
    }
  ],
  "monitoring": [
    {
      "item": "MoCA or MMSE",
      "frequency": "Every 6-12 months",
      "action": "Decline >3 points or reaching dementia threshold warrants reassessment; consider biomarker workup if not done",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Full neuropsychological testing",
      "frequency": "Every 1-2 years or if significant change",
      "action": "Decline suggests progression to dementia; adjust care plan",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "IADL/ADL function (FAQ, Lawton)",
      "frequency": "Every 6-12 months",
      "action": "Functional decline suggests progression to dementia; increase supports",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Depression screening (GDS, PHQ-9)",
      "frequency": "Annually or if symptoms",
      "action": "Treat depression; reassess cognition after treatment",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Blood pressure",
      "frequency": "Each visit",
      "action": "Optimize antihypertensive therapy",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "HbA1c (if diabetic)",
      "frequency": "Every 3-6 months",
      "action": "Optimize glycemic control",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Lipid panel",
      "frequency": "Annually",
      "action": "Optimize statin therapy",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Vitamin B12",
      "frequency": "Annually",
      "action": "Supplement if low",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "TSH",
      "frequency": "Annually",
      "action": "Treat thyroid dysfunction",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "MRI (ARIA monitoring if on anti-amyloid)",
      "frequency": "Per protocol (baseline, weeks 14, 52, 78 for lecanemab)",
      "action": "Hold infusion per protocol; resume after resolution",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Driving safety",
      "frequency": "Annually or with decline",
      "action": "Recommend driving cessation or OT driving evaluation",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Weight",
      "frequency": "Each visit",
      "action": "Nutritional assessment if declining",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Caregiver/family concerns",
      "frequency": "Each visit",
      "action": "Investigate reported changes; adjust care plan",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    }
  ],
  "disposition": [
    {
      "disposition": "Outpatient management (most MCI)",
      "criteria": "Stable MCI; reversible causes addressed; care plan established; follow-up arranged"
    },
    {
      "disposition": "Admit to floor",
      "criteria": "Acute delirium requiring workup; safety concerns at home; caregiver crisis"
    },
    {
      "disposition": "Outpatient neurology follow-up",
      "criteria": "Every 6-12 months for cognitive monitoring; sooner if concerns"
    },
    {
      "disposition": "Outpatient neuropsychology",
      "criteria": "At diagnosis for baseline; repeat in 1-2 years or if significant change"
    },
    {
      "disposition": "Referral to memory care program",
      "criteria": "Progressive decline; need for specialized multidisciplinary management"
    },
    {
      "disposition": "Clinical trial referral",
      "criteria": "Eligible patient interested in research; positive biomarkers; early stage"
    }
  ]
}